In the field of pharmaceuticals, Beijing Wenfeng Tianji Pharmaceutical Technology Co., Ltd.is the research center and Guangdong Zhonghao Pharmaceutical Co., Ltd. is the industrialization base. Our own the complete intellectual property of the State CategoryⅠNew Drug Benvitimod in China. Benvitimod is the new generation non-steroidal small molecule chemicals in inflammatory and autoimmune diseases therapeutic fields, and it is also the first therapeutic aryl hydrocarbon receptor modulating agent (TAMA).
Benvitimod can be used in the treatment of some autoimmune diseases/ inflammatory allergic diseases, such as psoriasis. It is in the international leading level in above therapeutic field and was listed as “Significant New Drugs Development” achievement of National Science and Technology Major Project in "The 11th Five-Year Plan"and "The 12th Five-Year Plan" by National Ministry of Science and Technology.
The overall structure of the pharmaceutical sector is complete, which totally covered the whole process includes of research and development, manufacturing and marketing of new drugs. It has the "one-stop" type abilities of comprehensive industrial transformation and market operation.
Symbiox® ——an innovative product in topic treatment of Psoriasis in worldwide for the past 30 years.
·In 31 May 2019, Benvitimod (Commodity Name: Symbiox® ) was approved by Center for Drug Evaluation as State CategoryⅠNew Drug for the treatment of mild to moderate Psoriasis vulgaris.
·In July 2019, Ministry of Science and Technology published an article “Benvitimod, the worldwide innovative psoriasis drug, was approved by CDE” on its website.
·In October 2019, launch ceremony of Benvitimod named “Innovation of China leading the world” was held in the Great Hall of the People in Beijing.
·State CategoryⅠNew Drug、National Science and Technology Major Project、”Significant New Drugs Development”、obtained Intellectual Property Protection in China.
·Delay relapse: After 12 weeks of treatment, patients in the benvitimod group achieved a median remission period of 36 weeks.
·Better efficacy: 50 % of patients achieved PASI 75 at week 12 in the benvitimod group, which was significantly higher than that in either the calcipotriol group.
·Higher safety: Almost no systemic adverse drug reactions were found.
·Tripartite effects: Benvitimod can target to AhR, and prevent psoriasis recurrence.